Details for Patent: 8,877,776

Which drugs does patent 8,877,776 protect, and when does it expire?

Patent 8,877,776 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has seventy-two patent family members in twenty-six countries.

Summary for Patent: 8,877,776

Title:	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de
Abstract:	Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cy- clopropane -1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-cy- clopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-ffuorophenyl)cyc- lopropane-1,1-dicarboxamide.
Inventor(s):	Brown; Adrian St. Clair (Ely, GB), Lamb; Peter (Oakland, CA), Gallagher; William P. (Princeton, NJ)
Assignee:	Exelixis, Inc. (South San Francisco, CA)
Application Number:	13/145,054
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,877,776
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 8,877,776

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y	Y		METHOD OF TREATING MEDULLARY THYROID CANCER
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes			Y	Y		METHOD OF TREATING MEDULLARY THYROID CANCER
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No			Y	Y		TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No			Y	Y		TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY

Foreign Priority and PCT Information for Patent: 8,877,776

PCT Information
PCT Filed	January 15, 2010	PCT Application Number:	PCT/US2010/021194
PCT Publication Date:	July 22, 2010	PCT Publication Number:	WO2010/083414

International Family Members for US Patent 8,877,776

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	075025
Australia	2010204619
Australia	2013203780
Australia	2016262732